Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1687-1692

  Bender, Hans ^a   Kirst, Jens ^a   Palmedo, Holger ^a   Schomburg, Axel ^a   Wagner, Uwe ^a   Ruhlmann, Jürgen ^a   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

18 fluoro deoxyglucose positron emission tomography; Breast carcinoma; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; BONE TUMOR; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LABORATORY DIAGNOSIS; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; DEOXYGLUCOSE; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030610282     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23: 1641-1674, 1996.
2. Henderson IC, Harris JR, Kinne DW, Hellman S: Cancer of the breast. In Cancer. Principles and Practice of Oncology. eds. DeVita VT, Hellman S, Rosenberg SA; JB Lippincott Company, Philadelphia, 1989.
3. Bastert G und Costa SD: Therapie des Mammakarzinoms. In Onkologie. Grundlagen, Diagnostik, Therapie, Entwicklungen. eds. Zeller WJ, Zur Hausen H; Ecomed, Landsberg, 1995.
4. Minn H, Soini I: (18F)Fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 15: 61-66, 1989.
5. Wahl RL, Cody R, Hutchins G et al: Positron emission tomographic scanning of primary and metastatic breast with radiolabeled glucose analogue 2-deoxy-2-(18F)fluoro-D-glucose. Radiology 179: 765-770, 1991.
6. Wahl RL, Cody R, Hutchins G et al: Primary and metastatic breast carcinoma: initial evaluation with PET with radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. N Engl J Med 324: 200 1991.
7. Kubota K, Matsuzawa T, Ameniya A et al: Imaging of breast cancer with (18F)Fluorodeoxyglucose and positron emission tomography. J Comput. Assist Tomogr 13: 1097-1098, 1989.
8. Nieweg OE, Kim EE, Wong WH et al: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71: 3920-3925, 1993.
9. 18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 17: 582-589, 1993.
10. Utech CI, Young CS, Winter PF et al: Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23: 1588-1593, 1996.
11. Bender H, Hamad K, Frohman JP et al: Staging of malignant melanoma: Value of whole-body FDG-PET and radioimmunoscintigraphy. Eur. J Nucl Med 23: 1106, 1996.